Efficacy and safety of insulin detemir versus glargine in patients with diabetes: a systematic review and meta-analysis

References

• Mellitus D. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2005;28(S37):S5–S10.
   Google Scholar
• Riddle MC, Herman WH. The cost of diabetes care—an elephant in the room. Diabetes Care. 2018;41(5):929–932.
   Google Scholar
• Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes atlas. Diabetes Res Clin Pract. 2019;157:107843.
   Google Scholar
• Association AD. Economic costs of diabetes in the US in 2017. Diabetes Care. 2018;41(5):917–928.
   Google Scholar
• Cho N, Shaw J, Karuranga S, et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–281.
   Google Scholar
• Forouhi NG, Wareham NJ. Epidemiology of diabetes. Medicine (Baltimore). 2019;47(1):22–27.
   Google Scholar
• Chun J, Strong J, Urquhart S. Insulin initiation and titration in patients with type 2 diabetes. Diabetes Spectr. 2019;32(2):104–111.
   Google Scholar
• Association AD. Summary of revisions: standards of medical care in diabetes—2019. Diabetes Care. 2019;42(Supplement 1):S4–S6.
   Google Scholar
• Heise T, Pieber T. Towards peakless, reproducible and long‐acting insulins. an assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obesity Metab. 2007;9(5):648–659.
   Google Scholar
• Dunn CJ, Plosker GL, Keating GM, et al. Insulin glargine. Drugs. 2003;63(16):1743–1778.
   Google Scholar
• Chapman TM, Perry CM. Insulin Detemir. Drugs. 2004;64(22):2577–2595.
   Google Scholar
• De Souza ALC, de Assis Acurcio F, Júnior AAG, et al. Insulin glargine in a Brazilian state: should the government disinvest? An assessment based on a systematic review. Appl Health Econ Health Policy. 2014;12(1):19–32.
   Google Scholar
• Yki-Järvinen H, Kauppinen-Mäkelin R, Tiikkainen M, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia. 2006;49(3):442–451.
   Google Scholar
• Hermansen K, Davies M, Derezinski T, et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care. 2006;29(6):1269–1274.
   Google Scholar
• Philis-Tsimikas A, Charpentier G, Clauson P, et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther. 2006;28(10):1569–1581.
   Google Scholar
• Semlitsch T, Engler J, Siebenhofer A, et al. (Ultra‐) long‐acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2020;11. DOI: 10.1002/14651858.CD005613.pub4.
   Google Scholar
• Hemmingsen B, Metzendorf M-I, Richter B. (Ultra‐) long‐acting insulin analogues for people with type 1 diabetes mellitus. Cochrane Database Syst Rev. 2021. 3. DOI: 10.1002/14651858.CD013498.pub2.
   Google Scholar
• Tricco AC, Ashoor HM, Antony J, et al. Comparative efficacy and safety of ultra-long-acting, long-acting, intermediate-acting, and biosimilar insulins for type 1 diabetes mellitus: a systematic review and network meta-analysis. J Gen Intern Med. 2021;1–13.
   Google Scholar
• Godman B, Wladysiuk M, McTaggart S, et al. Utilisation trend of long-acting insulin analogues including biosimilars across Europe: findings and implications. Biomed Res Int. 2021;2021:1–16.
   Google Scholar
• Meneghini LF, Sullivan SD, Oster G, et al., A pragmatic randomized clinical trial of insulin glargine 300 U/mL vs first‐generation basal insulin analogues in insulin‐naïve adults with type 2 diabetes: 6‐month outcomes of the ACHIEVE Control study. Diabetes Obesity Metab. 22(11): 2004–2012. 2020.
   Google Scholar
• Elisha B, Azar M, Taleb N, et al. Body composition and epicardial fat in type 2 diabetes patients following insulin detemir versus insulin glargine initiation. Hormone Metab Res. 2016;48(1):42–47.
   Google Scholar
• Meneghini L, Kesavadev J, Demissie M, et al. Once‐daily initiation of basal insulin as add‐on to metformin: a 26‐week, randomized, treat‐to‐target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes. Diabetes Obesity Metab. 2013;15(8):729–736.
   Google Scholar
• Swinnen SG, Dain M-P, Aronson R, et al., A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. Diabetes Care. 33(6): 1176–1178. 2010.
   Google Scholar
• Raskin P, Gylvin T, Weng W, et al. Comparison of insulin detemir and insulin glargine using a basal‐bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. Diabetes Metab Res Rev. 2009;25(6):542–548.
   Google Scholar
• Fadini G, De Kreutzenberg S, Mariano V, et al. Optimized glycaemic control achieved with add‐on basal insulin therapy improves indexes of endothelial damage and regeneration in type 2 diabetic patients with macroangiopathy: a randomized crossover trial comparing detemir versus glargine. Diabetes Obesity Metab. 2011;13(8):718–725.
   Google Scholar
• Rosenstock J, Davies M, Home P, et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia. 2008;51(3):408–416.
   Google Scholar
• Hollander P, Cooper J, Bregnhøj J, et al. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther. 2008;30(11):1976–1987.
   Google Scholar
• Bhosle DS, Bobde JA, Patil AD, et al. A comparative, randomized pilot study of insulin glargine versus insulin detemir as add-on therapy in uncontrolled type 2 diabetic patients. Journal of Obesity and Metabolic Research. 2014;1(4):209.
   Google Scholar
• Renard E, Dubois-Laforgue D, Guerci B, et al. Non-inferiority of insulin glargine versus insulin detemir on blood glucose variability in type 1 diabetes patients: a multicenter, randomized, crossover study. Diabetes Technol Ther. 2011;13(12):1213–1218.
   Google Scholar
• Heller S, Koenen C, Bode B. Comparison of insulin detemir and insulin glargine in a basal—bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, Treat-to-Target noninferiority trial. Clin Ther. 2009;31(10):2086–2097.
   Google Scholar
• Pieber T, Treichel HC, Hompesch B, et al., Comparison of insulin detemir and insulin glargine in subjects with type 1 diabetes using intensive insulin therapy. Diabetic Med. 24(6): 635–642. 2007.
   Google Scholar
• Group AC. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572.
   Google Scholar
• Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–1589.
   Google Scholar
• Pedersen O, Gæde P. Intensified multifactorial intervention and cardiovascular outcome in type 2 diabetes: the Steno-2 study. Metabolism. 2003;52:19–23.
   Google Scholar
• Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Bmj. 2000;321(7258):405–412.
   Google Scholar
• Silva TB, Almeida PH, Araújo VE, et al., Effectiveness and safety of insulin glargine versus detemir analysis in patients with type 1 diabetes: systematic review and meta-analysis. Ther Adv Endocrinol Metab. 9(8): 241–254. 2018.
   Google Scholar
• Association AD. 6. Glycemic targets: standards of medical care in diabetes—2019. Diabetes Care. 2019;42(Supplement 1):S61–S70.
   Google Scholar
• Pi-Sunyer FX. The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus. Postgrad Med. 2009;121(5):94–107.
   Google Scholar
• Wadsworth TG, Carr GG, Madaras-Kelly K, et al. Weight gain associated with insulin detemir vs insulin glargine in clinical practice: a retrospective longitudinal cohort study. Am J Health Syst Pharm. 2021;78(5):401–407.
   Google Scholar
• Torimoto K, Okada Y, Hajime M, et al. Risk factors of hypoglycemia in patients with type 2 diabetes mellitus: a study based on continuous glucose monitoring. Diabetes Technol Ther. 2018;20(9):603–612.
   Google Scholar
• George J, Giuliano CA, Hartner CL. Glycemic variability with insulin glargine versus detemir in hospitalized patients with diabetes. J Pharm Pract. 2021;08971900211017867.
   Google Scholar
• Veneman TF, Storms FE, Eland IA, et al. From insulin detemir to glargine: effect on glycemic control and psychological wellbeing in patients with diabetes mellitus type 2 in daily practice. Journal of Diabetes Mellitus. 2012;02(1):101–108.
   Google Scholar
• Swinnen SG, Simon AC, Holleman F, et al. Insulin detemir versus insulin glargine for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2011(7). DOI: 10.1002/14651858.CD006383.pub2.
   Google Scholar